Our Mission

Phoenix Molecular Designs is a female-founded company led by experts in breast cancer, who have dedicated decades of their lives to developing new therapies for patients and their families.

Our steadfast mission is to develop precise cancer therapies centered around RSK-dependent cancers. Until now, RSK was thought to be undruggable, however, the Phoenix team cracked the chemistry code using artificial intelligence and computational modeling. Our leadership team boasts previous expertise in developing FDA-approved drugs for breast cancer and has entered partnerships with well-recognized government and academic research institutions.

Phoenix has intentionally centered the patient experience at every stage of development. PMD-026 was designed as a pill to emphasize convenience and to allow patients the comfort and flexibility of medicating at home. We also believe that one size does not fit all and are determined to deliver the right therapy to the right patient. It is for this reason that we developed a companion diagnostic so that patients can be confident that PMD-026 will directly target their tumor type.

Our Motivation

We are drug hunters motivated by solving complex problems in the treatment of cancer so that people can live longer. Precise cancer therapies have a proven track record of giving patients longer lives however, more options are needed.

There are untapped opportunities to treat cancer, that’s where we come in.

Cancer is a complex disease that is simplified by the discovery of genes that control its growth.
R S K – Ribosomal S-6 Kinase is a family of genes that control cancer growth. This family includes RSK1, RSK2, RSK3, RSK4
We discovered RSK2 is essential for the growth of breast cancer.

Our Vision

Phoenix Molecular Designs’ vision is to precisely treat cancer through RSK inhibition.

Our precision medicine approach is to develop a complete therapeutic solution for patients with RSK-dependent cancers. We can identify who to treat using our companion diagnostic, RSK2 CDXV1.0 and we know how to treat those patients using our RSK-targeted therapy PMD-026.

For patients with RSK-dependent cancers, we have you covered.